| Micro-channel |
 |
|
|
|
|
|
| |
| What is the number of Chinese medicine in the nose and throat market? |
| |
| Author：中國銘鉉 企劃部 Release Time：2017-9-27 11:07:47 Number Browse：1722 |
| |
On September 26, the medical network reported that the white dew had passed, and immediately entered the autumn equinox, and then in the period of high incidence of otolaryngological diseases, how did the domestic drug market perform?
Otolaryngology head face the beginning of the opening to the outside world for the human body, vulnerable to the environment, the physical, chemical and biological factors adverse stimulation in structure and function obstacle, in the majority with a variety of inflammatory lesions. Ent disease including ear disease, the nose and throat diseases, ent are mutually connected, the nose and throat order, pharynx ministry through the eustachian tube and ear are interlinked, often a single part can drag in other parts of the disease.
Seasonal change is one of the causes of otolaryngology, which is the time when the summer and fall alternate, the climate is dry, the cold and the changeable, and the time of the ear nose and throat disease is high. Other modern life rhythm speeding up, irregular nightlife, do not pay attention to diet, it is easy to cause human body disease-resistant ability, coupled with the environmental pollution is serious, now airborne dust, superposition of multiple factors made continued high incidence of ear-nose-throat of related diseases.
The total size is 15.1 billion yuan
The proportion of pharyngeal agents is nearly 70%
According to the China kang CMH monitoring data, in 2016, China's five major terminal otolaryngological drugs reached 15.1 billion yuan, of which the proportion of the pharyngeal agents accounted for 69.6 percent of the total, while the nasal preparations accounted for 28.7 percent of the total. In recent years, the drug market of otolaryngology has been on a steady upward trend, with year-on-year growth of more than 8% in three consecutive years, with an annual growth rate of 8.2% in 2016. The throat in preparation, nasal preparation and drug otology share of relatively stable, but from their respective growth rates, otology grew fastest in 2016, to 16.7%, preparations and nasal and throat with phase close, at around 8%.
Figure 1. Market size of otolaryngology drug market in 2013-2016 (unit: billion yuan)
Figure 2. The changes in the proportion of otolaryngology drugs in the ear and nose in 2013-2016
Chinese medicine is the best medicine
But there are a lot of differences
Of the five major terminal ent use proprietary Chinese medicine in 2016 market size is 12.66 billion yuan, the market share as high as 84.1%, compared with the five terminal category data all proprietary Chinese medicine market share of only 38.1%, proprietary Chinese medicine in the field of ent drugs.
In the case of separating the throat, nasal preparation and ear, the proportion of Chinese medicine is high, mainly affected by the pharyngeal preparation. The market share of the drug used for throat preparation is up to 97.5%, including heat reagent, nourishing agent, treating wind agent, clearing damp and removing stasis. The use of nasal preparations and ear drugs was far worse than that of pharyngeal agents, with 58.7 percent of the nasal preparations and only 43.8 percent of the total.
FIG. 3 Chinese and western classification of otolaryngology in 2016
There are obvious differences in the route of medicine
The main methods for the administration of otolaryngology include internal and oral cavity/mucosa. Overall, the internal service ratio has an advantage, accounting for 67.4 percent of the total in 2016, but the difference in market performance of various drugs is significant in the light of the difference of throat preparation, nasal preparation and ear medicine. The main drug of the pharynx is mainly medicine, which is 75.6% in 2016, while the nasal preparation and ear medicine have the particularity of the medicine. Nasal preparation, drug use in the nasal cavity and nasal mucosa absorption can give play to the role of local or systemic treatment, ear can be directly used for drug ear give play to the role of local treatment, nasal preparations and otology medicine dosage orifices/mucous membrane is slightly better, especially in otology, accounted for 58.5% in 2016.
Figure 4. Classification of drug administration of otolaryngology in 2016
Top 10 market performance of popular products
In terms of the best-selling products, the market share of the throat preparation market is the largest in the market, with a share of 23.3%. The market share in the hospital market and retail pharmacy has maintained a fast growth rate, and the market share in 2016 has increased greatly from 2015. According to the EI index, lanqin oral liquid, clear throat, new leaf, compound tablet and compound fish houttuynia mixture have relatively high development level.
Table 1. Top 10 share and growth of the popular products of throat preparation products
Nasal preparation products, best-selling budesonide nasal spray and fluticasone propionate nasal spray market share of more than 10%, both for the cavity/mucosal drug delivery products, but share slightly down compared to last year. According to the EI index, the fastest growing share is xiangju capsule, followed by the tongqiao rhinitis granule, all of which are oral products.
Table 2. TOP10 share and growth of the popular products of nasal preparation products
The market concentration of the ear drug administration is high, and the share of products of the ten products was up to 97.4% before 2016. Best-selling products, there are two types of ear drops fight infection (ofloxacin ear drops, maintain hydrochloride ear drops) and two oral Chinese patent medicine (deafness capsule, deaf left Keats pill) products market share of more than 10%. According to the EI index, the most rapid increase in the share of the hydrochloric acid is the ear drops, followed by levofloxacin hydrochloric acid, which is the anti-infective ear drops.
Table 3. TOP10 share and growth of the best-selling products of the ear drug
Note: EI is based on 100, indicating the average development level of category; EI>100 indicates that product development is above average; EI<100 indicates that product development is below average.
Data source: zhongkang CMH
|
| |
Previous article：Is it the next blue ocean to expand the new market for medical food
Next article：CFDA director: GMP, GSP certification will be cancelled!
|
| |
|
|
